KRAS and colorectal carcinoma: In four CRC patient-derived models, including two KRAS wild- type and two KRAS mutant models (van de Wetering et al., 2015), KRAS wild-type MOSs were more sensitive to anti-EGFR treatments than the two KRAS mutant MOSs (Figure 5G).